Ivermectin for Malaria Vector Control: Mechanisms and Clinical Evidence
Ivermectin kills Anopheles mosquitoes feeding on treated hosts and is being evaluated as a complementary malaria vector control tool. This narrative review synthesizes evidence regarding glutamate-gated chloride channels (GluCl), mosquito-lethal human metabolites, effects on Plasmodium sporogony, and clinical trial outcomes. A structured PubMed search identified mechanistic, entomological, pharmacokinetic, and clinical studies published primarily between 2016 and 2026. Laboratory studies demonstrate biological plausibility, showing mosquito mortality and impaired sporogony. Human metabolites also contribute significantly to mosquitocidal activity. However, population-level evidence remains inconsistent. While a Kenyan trial demonstrated reduced malaria infection incidence, the Mozambique BOHEMIA trial faced operational disruptions, and RIMDAMAL II in Burkina Faso showed no significant incidence reduction when combined with seasonal malaria chemoprevention. Furthermore, a 2026 meta-analysis confirmed stronger evidence for mosquito mortality than for consistent epidemiological benefits. Thus, ivermectin is a promising investigational adjunct rather than a replacement for core interventions. Future research must standardize endpoints, optimize dosing, and evaluate context-specific effectiveness.
Authors
- Mike Permata Sari
- Afifa Radhina
- Nurul Ain
Institutions
- Syarif Hidayatullah State Islamic University Jakarta (ID)
- Universitas Pembangunan Nasional Veteran Jakarta (ID)
- Institut Kesehatan Hermina (ID)
Publication Details
- Journal
- Health & Medical Sciences
- Published
- 2026-11-18
- DOI
- https://doi.org/10.47134/phms.v4i1.810
- Primary Topic
- Malaria Research and Control
- Type
- article
- Field-Weighted Citation Impact
- 0.00